Visit https://www.peervoice.com/APW860 to view the entire programme with slides. After completing “Michael Heuser, MD - Case Study Challenge: Managing FLT3-ITD–Positive AML”, participants will be able to: Implement evidence-based best practice approaches to management of newly diagnosed FLT3-ITD–positive acute myeloid leukaemia (AML); Recognise adverse events associated with the use of FLT3 inhibitors and strategies to monitor for and manage these events; and Assess the real-world considerations of utilising measurable residual disease (MRD) as a clinical biomarker in the management of AML.